速尿
内科学
内分泌学
胆固醇
摄入
交叉研究
脂蛋白
医学
载脂蛋白B
血脂谱
安慰剂
病理
替代医学
作者
Norm R.C. Campbell,Rollin Brant,Helga Stalts,James A. Stone,Houman Mahallati
出处
期刊:Archives of internal medicine
[American Medical Association]
日期:1998-07-13
卷期号:158 (13): 1461-1461
被引量:23
标识
DOI:10.1001/archinte.158.13.1461
摘要
Background
Acute decreases in intravascular volume are associated with increases in lipid levels. Furosemide causes acute changes in intravascular volume during prolonged therapy but is thought to have little effect on lipid levels. Methods
To determine if there are daily acute rises in lipid and lipoprotein levels associated with changes in intravascular volume during long-term furosemide ingestion therapy, we performed a randomized, double-blind, placebo-controlled crossover study in 10 patients. Results
In the 8 hours after furosemide ingestion there were increases in levels of plasma cholesterol (10.1%;P=.001), high-density lipoprotein cholesterol (9.0%;P=.006), and apolipoprotein B (9.8%;P=.003). The increases in levels of triglycerides (11.5%;P=.17) and apolipoprotein A-1 (13.3%;P=.051) were of similar magnitude but more variable and did not achieve statistical significance. There was no substantial change in the total cholesterol–high-density lipoprotein cholesterol ratio (0.6%; 95% CI,−0.74% to 8.6%;P=.88). Conclusion
This study indicates that there are acute increases in lipid levels after furosemide ingestion during prolonged therapy, which could affect the interpretation of lipid levels and cardiovascular risk in patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI